The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Open accessAbstract
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC‐inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non‐oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA‐approved agents; however, it often results in increased treatment‐related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183
RetractedRAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies
Stamatakis, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu033 · Cited by 32,291
MRBAYES: Bayesian inference of phylogenetic trees.
Huelsenbeck, J. P., & Ronquist, F. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.8.754 · Cited by 21,937
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
PubChem 2019 update: improved access to chemical data
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1033 · Cited by 3,249
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.786 · Cited by 2,639
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 6×
“Hyperacetylation of the chaperone protein HSP90 can lead to the release and subsequent degradation of various oncogenic client proteins.(9,55) HDAC inhibitors have also been shown to downregulate MYC expression in some solid tumours and leukaemia.”
BackgroundInfluentialKawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019) · Blood · doi:10.1182/blood-2018-11-881268 · Cited by 1,412
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Sodium butyrate inhibits histone deacetylation in cultured cells
Candido, E. (1978) · Cell · doi:10.1016/0092-8674(78)90305-7 · Cited by 1,036
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease
Ito, K., Ito, M., Elliott, W. M., Cosio, B., Caramori, G., Kon, O. M., Barczyk, A., Hayashi, S., Adcock, I. M., Hogg, J. C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041892 · Cited by 968
Yang, X.-J., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210599 · Cited by 940
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Self-citationMAFFT-DASH: integrated protein sequence and structural alignment
Rozewicki, J., Li, S., Amada, K. M., Standley, D. M., & Katoh, K. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz342 · Cited by 814
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
San-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4223 · Cited by 680
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Rasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β-catenin–TCF interaction
Ye, F., Chen, Y., Hoang, T., Montgomery, R. L., Zhao, X.-H., Bu, H., Hu, T., Taketo, M. M., van Es, J. H., Clevers, H., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2333 · Cited by 559
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
Mihaylova, M. M., Vasquez, D. S., Ravnskjaer, K., Denechaud, P.-D., Yu, R. T., Alvarez, J. G., Downes, M., Evans, R. M., Montminy, M., & Shaw, R. J. (2011) · Cell · doi:10.1016/j.cell.2011.03.043 · Cited by 533
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005142 · Cited by 516
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14752 · Cited by 505
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.006 · Cited by 352
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 326
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Kelly, R. D. W., & Cowley, S. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130010 · Cited by 297
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Self-citationJiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Allogeneic transfusion and infection: economic and clinical implications.
Sonneveld, P., Lokhorst, H. M., & Vossebeld, P. J. M. (1997) · PubMed · Cited by 267
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0439-6 · Cited by 246
Cloning and characterization of a histone deacetylase, HDAC9
Zhou, X., Marks, P. A., Rifkind, R. A., & Richon, V. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191375098 · Cited by 245
Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo
Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., & Verdin, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104935200 · Cited by 232
Vojinovic, J., Damjanov, N., D'Urzo, C., Furlan, A., Susic, G., Pasic, S., Iagaru, N., Stefan, M., & Dinarello, C. A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30238 · Cited by 226
Hook, S. S., Orian, A., Cowley, S. M., & Eisenman, R. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172511699 · Cited by 224
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
Epigenetic control of skull morphogenesis by histone deacetylase 8
Haberland, M., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Genes & Development · doi:10.1101/gad.1809209 · Cited by 219
Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, B. G., & Verdin, E. (2003) · Immunity · doi:10.1016/s1074-7613(03)00109-2 · Cited by 212
Histological effects of givinostat in boys with Duchenne muscular dystrophy
Bettica, P., Petrini, S., D'Oria, V., D'Amico, A., Catteruccia, M., Pane, M., Sivo, S., Magri, F., Brajkovic, S., Messina, S., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.07.002 · Cited by 212
Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
Integrative regulation of physiology by histone deacetylase 3
Emmett, M. J., & Lazar, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0076-0 · Cited by 202
Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
Hai, Y., Shinsky, S. A., Porter, N. J., & Christianson, D. W. (2017) · Nature Communications · doi:10.1038/ncomms15368 · Cited by 200
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
ITAZAKI, H., NAGASHIMA, K., SUGITA, K., YOSHIDA, H., KAWAMURA, Y., YASUDA, Y., MATSUMOTO, K., ISHII, K., UOTANI, N., NAKAI, H., et al. (1990) · The Journal of Antibiotics · doi:10.7164/antibiotics.43.1524 · Cited by 197
Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation
Brunmeir, R., Lagger, S., & Seiser, C. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082649rb · Cited by 197
Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193
Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Belt, R. J., Jacobsen, E. D., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13222 · Cited by 193
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
Archin, N. M., Kirchherr, J. L., Sung, J. A. M., Clutton, G., Sholtis, K., Xu, Y., Allard, B., Stuelke, E., Kashuba, A. D., Kuruc, J. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92684 · Cited by 190
Leth, S., Schleimann, M. H., Nissen, S. K., Højen, J. F., Olesen, R., Graversen, M. E., Jørgensen, S., Kjær, A. S., Denton, P. W., Mørk, A., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30055-8 · Cited by 177
Histone deacetylase 11 is a fatty-acid deacylase
Kutil, Z., Novakova, Z., Meleshin, M., Mikesova, J., Schutkowski, M., & Barinka, C. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00942 · Cited by 174
Leipe, D. D., & Landsman, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.18.3693 · Cited by 168
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Lu, X., Ning, Z., Li, Z., Cao, H., & Wang, X. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01024 · Cited by 166
How I treat the peripheral T-cell lymphomas
Moskowitz, A. J., Lunning, M. A., & Horwitz, S. M. (2014) · Blood · doi:10.1182/blood-2013-12-516245 · Cited by 164
Epigenetic therapy for F riedreich ataxia
Soragni, E., Miao, W., Iudicello, M., Jacoby, D. B., Mercanti, S. F. D., Clerico, M., Longo, F., Piga, A., Ku, S., Campau, E., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24260 · Cited by 163
Friedreich Ataxia: current status and future prospects
Bürk, K. (2017) · Cerebellum & Ataxias · doi:10.1186/s40673-017-0062-x · Cited by 163
Ghosh, S. K., Perrine, S. P., Williams, R. M., & Faller, D. V. (2012) · Blood · doi:10.1182/blood-2011-06-362434 · Cited by 160
Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.002 · Cited by 159
Lenoir, O., Flosseau, K., Ma, F. X., Blondeau, B., Mai, A., Bassel‐Duby, R., Ravassard, P., Olson, E. N., Haumaître, C., & Scharfmann, R. (2011) · Diabetes · doi:10.2337/db11-0440 · Cited by 156
Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management
Hristov, A. C., Tejasvi, T., & Wilcox, R. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25577 · Cited by 150
Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
Moreno-Yruela, C., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.04.007 · Cited by 149
Dovey, O. M., Foster, C. T., Conte, N., Edwards, S. A., Edwards, J. M., Singh, R., Vassiliou, G. S., Bradley, A., & Cowley, S. M. (2013) · Blood · doi:10.1182/blood-2012-07-441949 · Cited by 148
Malhotra, R. K., Mauer, A. C., Cardenas, C. L. L., Guo, X., Yao, J., Zhang, X., Wunderer, F., Smith, A. V., Wong, Q., Pechlivanis, S., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0514-8 · Cited by 147
Waltregny, D., de Leval, L., Glénisson, W., Tran, S. L., North, B. J., Bellahcène, A., Weidle, U. H., Verdin, E. M., & Castronovo, V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63320-2 · Cited by 134
Amengual, J. E., Lichtenstein, R., Lue, J. K., Sawas, A., Deng, C., Lichtenstein, E., Khan, K. A., Atkins, L. E., Rada, A. M., Kim, H. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-806737 · Cited by 134
Histone deacetylase inhibitors and HIV latency
Margolis, D. M. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328341242d · Cited by 133
Richardson, P. G. G., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2015) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 133
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 125
Patnaik, A., Rowinsky, E. K., Villalona, M. A., Hammond, L. A., Britten, C. D., Siu, L. L., Goetz, A. D., Felton, S., Burton, S., Valone, F. H., et al. (2002) · PubMed · Cited by 124
HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine
Aramsangtienchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00396 · Cited by 118
Sandi, C., Pinto, R. M., Al‐Mahdawi, S., Ezzatizadeh, V., Barnes, G., Jones, S. E., Rusche, J. R., Gottesfeld, J. M., & Pook, M. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.016 · Cited by 118
Wolf, J. L., Siegel, D. S. D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B., Matous, J., Vij, R., Magalhaes-Silverman, M. D., Abonour, R., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.661175 · Cited by 116
HDAC11 is a regulator of diverse immune functions
Yanginlar, C., & Logie, C. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.12.002 · Cited by 113
Mechanisms of Resistance to Histone Deacetylase Inhibitors
Lee, J., Choy, M. L., & Marks, P. A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00002-1 · Cited by 110
Chemical and structural biology of protein lysine deacetylases
Yoshida, M., Kudo, N., Kosono, S., & Ito, A. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.019 · Cited by 109
Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice
Wiley, J. C., Pettan-Brewer, C., & Ladiges, W. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00680.x · Cited by 108
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats
Lundh, M., Galbo, T., Poulsen, S. S., & Mandrup-Poulsen, T. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12470 · Cited by 104
Targeting histone deacetylases in T-cell lymphoma
Moskowitz, A. J., & Horwitz, S. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1247956 · Cited by 103
Duvic, M. A., Olsen, E. A., Breneman, D., Pacheco, T. R., Parker, S. R. S., Vonderheid, E. C., Abuav, R., Ricker, J. L., Rizvi, S., Chen, C., et al. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.082 · Cited by 100
Liang, X., Zang, J., Li, X., Tang, S., Huang, M., Geng, M., Chou, C. J., Li, C., Cao, Y.-C., Xu, W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01597 · Cited by 99
Heideman, M. R., Wilting, R. H., Yanover, E., Velds, A., de Jong, J., Kerkhoven, R. M., Jacobs, H., Wessels, L. F. A., & Dannenberg, J. (2013) · Blood · doi:10.1182/blood-2012-08-450916 · Cited by 98
Пили, Р., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T. E., Shen, L., Orillion, A. R., Lamonica, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1178 · Cited by 97
Phuphanich, S., Baker, S. D., Grossman, S. A., Carson, K. A., Gilbert, M. R., Fisher, J. D., & Carducci, M. A. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000183 · Cited by 91
Reddy, S. D., Clossen, B. L., & Reddy, D. S. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244939 · Cited by 90
Derivatives of butyric acid as potential anti‐neoplastic agents
Rephaeli, A., Rabizadeh, E., Aviram, A., Shaklai, M., Ruse, M., & Nudelman, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490113 · Cited by 86
A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
Sato, T., Verma, S., Andrade, C. D. C., Omeara, M., Campbell, N., Wang, J. S., Cetinbas, M., Lang, A., Ausk, B. J., Brooks, D. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17099-3 · Cited by 86
Ma, C., & D’Mello, S. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.146860 · Cited by 83
Daneshpajooh, M., Bacos, K., Bysani, M., Bagge, A., Ottosson-Laakso, E., Vikman, P. J., Eliasson, L., Mulder, H., & Ling, C. (2016) · Diabetologia · doi:10.1007/s00125-016-4113-2 · Cited by 83
Exploring the epigenetic drug discovery landscape
Prachayasittikul, V., Prathipati, P., Pratiwi, R., Phanus‐umporn, C., Malik, A. A., Schaduangrat, N., Seenprachawong, K., Wongchitrat, P., Supokawej, A., Prachayasittikul, V., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1295954 · Cited by 81
Koeneke, E., Witt, O., & Oehme, I. (2015) · Cells · doi:10.3390/cells4020135 · Cited by 77
Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1
Campbell, G. R., Bruckman, R. S., Chu, Y.-L., & Spector, S. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605428 · Cited by 72
Caponigro, F., Gennaro, E. D., Ionna, F., Longo, F., Aversa, C., Pavone, E., Maglione, M. G., Marzo, M. D., Muto, P., Cavalcanti, E., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2957-y · Cited by 72
Woo, S., Gardner, E. R., Chen, X., Ockers, S. B., Baum, C. E., Sissung, T. M., Price, D. K., Frye, R., Piekarz, R., Bates, S. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1215 · Cited by 71
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 69
Self-citationDummer, R., Beyer, M., Hymes, K. B., Epping, M. T., Bernards, R., Steinhoff, M., Sterry, W., Kerl, H., Heath, K., Ahern, J. D., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.656625 · Cited by 65
Nilubol, N., Merkel, R., Yang, L., Patel, D., Reynolds, J. C., Sadowski, S. M., Neychev, V. K., & Kebebew, E. (2016) · Clinical Endocrinology · doi:10.1111/cen.13154 · Cited by 63
Panobinostat and Multiple Myeloma in 2018
Yee, A. J., & Raje, N. S. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0644 · Cited by 61
Kaufman, J. L., Mina, R., Jakubowiak, A. J., Zimmerman, T. L., Wolf, J. J., Lewis, C. M., Gleason, C. L., Sharp, C., Martin, T. G., Heffner, L. T., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0154-8 · Cited by 54
Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling
Hsu, A., Duan, Q., McMahon, S., Huang, Y., Wood, S. A. B., Gray, N. S., Wang, B., Bruneau, B. G., & Haldar, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133753 · Cited by 54
Epigenetic promoter silencing in F riedreich ataxia is dependent on repeat length
Chutake, Y. K., Lam, C. C., Costello, W. N., Anderson, M. P., & Bidichandani, S. I. (2014) · Annals of Neurology · doi:10.1002/ana.24249 · Cited by 53
Bradley, E. W., Shull, L. C., Olson, E. N., & Westendorf, J. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596247 · Cited by 53
PTHrP targets HDAC4 and HDAC5 to repress chondrocyte hypertrophy
Nishimori, S., Lai, F., Shiraishi, M., Kobayashi, T., Kozhemyakina, E. A., Yao, T., Lassar, A. B., & Kronenberg, H. M. (2019) · JCI Insight · doi:10.1172/jci.insight.97903 · Cited by 53
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Hamberg, P., Woo, M. M., Chen, L., Verweij, J., Porro, M. G., Zhao, L., Li, W., van der Biessen, D. A. J., Sharma, S., Hengelage, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1693-x · Cited by 45
HDAC11 Inhibits Myoblast Differentiation through Repression of MyoD-Dependent Transcription
Byun, S. K., An, T. H., Son, M. J., Lee, D. S., Kang, H. S., Lee, E., Han, B., Kim, W. K., Bae, K., Oh, K., et al. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0116 · Cited by 45
Offidani, M., Polloni, C., Cavallo, F., Liberati, A. M., Ballanti, S., Pulini, S., Catarini, M., Alesiani, F., Corvatta, L., Gentili, S., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.664844 · Cited by 44
Popat, R., Brown, S., Flanagan, L. M., Hall, A., Gregory, W. M., Kishore, B., Streetly, M. J., Oakervee, H. E., Yong, K., Cook, G., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30165-x · Cited by 43
Goey, A. K. L., Sissung, T. M., Peer, C. J., Trepel, J. B., Lee, M., Tomita, Y., Ehrlich, S., Bryla, C., Balasubramaniam, S., Piekarz, R., et al. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.625 · Cited by 41
Shinsky, S. A., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00079 · Cited by 41
Andrews, J. M., Schmidt, J. A., Carson, K. R., Musiek, A. C. M., Mehta–Shah, N., & Payton, J. E. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.053 · Cited by 41
Wong, N.-S., Seah, E., Wang, L., Yeo, W.-L., Yap, H., Chuah, B., Lim, Y.-W., Ang, P., Tai, B., Lim, R., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a8639 · Cited by 40
Vu, K., Wu, C.-H., Yang, C., Zhan, A., Cavallone, E., Berry, W., Heeter, P., Pincus, L. B., Wieduwilt, M. J., William, B. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2152 · Cited by 40
Iaconelli, J., Xuan, L. L., & Karmacharya, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071605 · Cited by 38
Berenson, J. R., Hilger, J. D., Yellin, O., Boccia, R. V., Matous, J., Dressler, K. P., Ghazal, H. H., Jamshed, S., Kingsley, E. C., Harb, W. A., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1910-2 · Cited by 36
Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
Sissung, T. M., Gardner, E. R., Piekarz, R., Howden, R., Chen, X., Woo, S., Franke, R. M., Clark, J. A., Miller‐DeGraff, L., Steinberg, S. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0925 · Cited by 34
Loss of HDAC11 accelerates skeletal muscle regeneration in mice
Núñez‐Álvarez, Y., Hurtado, E., Muñoz, M., García‐Tuñón, I., Rech, G. E., Pluvinet, R., Sumoy, L., Pendás, A. M., Peinado, M. A., & Suelves, M. (2020) · FEBS Journal · doi:10.1111/febs.15468 · Cited by 34
Chutake, Y. K., Lam, C. C., Costello, W. N., Anderson, M. P., & Bidichandani, S. I. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw107 · Cited by 29
Almeida, S., Gao, F., Coppola, G., & Gao, F. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.001 · Cited by 28
Shimony, S. O., Horowitz, N. A., Ribakovsky, E., Rozovski, U., Avigdor, A., Zloto, K., Berger, T., Avivi, I. M., Perry, C., Abadi, U., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2691 · Cited by 27
Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress Inhibition
Khan, S., Komarya, S. K., & Jena, G. (2017) · Epigenomics · doi:10.2217/epi-2016-0160 · Cited by 23
Manasanch, E. E., Shah, J. J., Lee, H. C., Weber, D. M., Thomas, S. K., Amini, B., Feng, L., Berkova, Z., Hildebrandt, M. A. T., & Orlowski, R. Z. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30174-1 · Cited by 18
Reid, T. R., Weeks, A., Vakil, M., Cosgriff, T. M., Harper, T., Valone, F. H., Magnuson, D., & Bhatnagar, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7279 · Cited by 16
Kogge, A., Volteau, C., Saint-Jean, M., Peuvrel, L., Brocard, A., Knol, A., Renaut, J., Dréno, B., & Quereux, G. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-1886 · Cited by 15
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma
Geskin, L. J., & Malone, D. C. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1412064 · Cited by 14
Zinzani, P. L., Pellegrini, C., Cerciello, G., Monaco, F., Volpetti, S., Peli, A., Angelucci, E., Corradini, P., Cox, M. C., Guarini, A., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1137292 · Cited by 7
Correction of Niemann-Pick type C1 disease with the histone deacetylase inhibitor valproic acidPreprint
Subramanian, K., Hutt, D. M., Gupta, V., Mao, S., & Balch, W. E. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724187 · Cited by 4
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Recent histone deacetylase inhibitors in cancer therapy
Parveen, R., Harihar, D., & Chatterji, B. P. (2023) · Cancer · doi:10.1002/cncr.34974 · Cited by 171
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Acetylation of histone H3 in cancer progression and prognosis
Miziak, P., Baran, M., Borkiewicz, L., Trombik, T., & Stepulak, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010982 · Cited by 49
Mazzocchi, M., Goulding, S. R., Morales-Prieto, N., Foley, T., Collins, L. M., Sullivan, A. M., & O'Keeffe, G. W. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.02.025 · Cited by 32
Metadata
- Authors
- Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2021-05-27
- Volume
- 87
- Issue
- 12
- Pages
- 4577-4597
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W3162317822
- Cited by
- 416
- References
- 159
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.